Brought to you by 
MediciNova gets two cardio compounds from Meiji Seika Kaisha
01 Sep 2011
Executive Summary
MediciNova has gained rights to two of Meiji Seika Kaisha's (infectious disease and neurological pharmaceuticals) small-molecule anti-thrombotic compounds. MN447 is in development for blood clot formation and MN462 for lysis; both have the potential for use in several thrombotic disorders. The worldwide license excludes Japan, Bangladesh, Brunei, Cambodia, the People's Republic of China, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MediciNova gets two cardio compounds from Meiji Seika Kaisha
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice